Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Alzamend Neuro, Inc. quarterly Debt-to-equity history and growth rate from Q4 2022 to Q2 2024.
Alzamend Neuro, Inc. Debt-to-equity for the quarter ending July 31, 2024 was -133 %, a 337% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period
Value
YoY Chg
Change %
Date
Q2 2024
-133
-190
-337%
Jul 31, 2024
Q1 2024
-147
-175
-619%
Apr 30, 2024
Q4 2023
-345
-361
-2188%
Jan 31, 2024
Q3 2023
195
Oct 31, 2023
Q2 2023
56.3
Jul 31, 2023
Q1 2023
28.3
Apr 30, 2023
Q4 2022
16.5
Jan 31, 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.